drugset / Trial / NCT04585789
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.
Timeline
- Start
- 2021-03-11
- Primary completion
- 2023-02-08
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-73763989 | Small interfering RNA (siRNA) | — | Subcutaneous |
| Background | Entecavir | Small molecule | — | Oral |
| Background | PegIFN-alpha-2a | Protein / enzyme biologic | — | Subcutaneous |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | Oral |
| Background | bersacapavir | Other / unclassified | — | Oral |
| Background | tenofovir alafenamide | Small molecule | — | Oral |